ClinicalTrials.gov
public full text
Public Domain
Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease
This study will perform a targeted metabolic analysis in blood and urine samples from subjects attending the Baylor AT\&T Memory Center. The aim is to identify novel biomarkers that can distinguish normal aging subjects with no cognitive impairment from those with mild, moderate or severe cognitive impairment associated with Alzheimer's disease. Subjects will also be screened for B-vitamin deficiencies that may correlate with other metabolic biomarkers and Alzheimer's disease.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Gut Microbiome Differences Between Early Alzheimer Disease and Idiopathic Normal Pressure Hydrocephalus.#297145
- Brain Health & the Microbiome#1152557
- Interaction-based metabolomics identifies serum modifiers of the clinical expression of Alzheimer's disease pathology#417393
- Discovery of novel metabolic biomarkers in blood serum for diagnosis of Alzheimer's disease.#662657
- Plasma Biomarkers and Clinical Outcomes in Early-Onset Dementia.#148155
Record · ID 895424
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive